ArticleEpilepsia2026
Emergency treatment delay and underdosing are associated with poor outcome in non-convulsive status epilepticus.
Article in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonconvulsive status epilepticus (NCSE) is difficult to recognize in the emergency department (ED), where onset is often unknown and treatment may be delayed. To what extent treatment timing and dose adequacy are associated with outcome in NCSE remains debated. In this single-center electroencephalography (EEG)-based study, adults with NCSE diagnosed in the ED were included. Timing was measured using ED arrival as a temporal anchor. Outcomes were failure to return to baseline at discharge and in-hospital mortality. Among 74 patients (mean age 66.8), 38 (51.4%) failed to return to baseline and 14 (18.9%) died. ED benzodiazepines (BDZs) were administered in 43 patients (58.1%) and anti-seizure medications (ASMs) in 71 (95.9%). Median times to BDZ and ASM administration were 184 and 223 min, respectively. After adjustment for Status Epilepticus Severity Score (STESS), potentially fatal etiology, and premorbid modified Rankin Scale score, time to ASM (odds ratio [OR]: 1.11 per hour; 95% confidence interval [CI]: 1.01-1.22; p = .037) and ASM underdosing (OR: 3.43; 95% CI: 1.10-10.68; p = .034) were independently associated with failure to return to baseline, with time to BDZ showing a non-significant trend. BDZ underdosing was not associated with functional outcome, and no treatment variable was associated with mortality. These findings support early EEG-based recognition and rapid, adequately dosed ASM treatment as key targets in ED-NCSE management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.